TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03629886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV (Types 16, 18) Vaccine, Adsorbed
Description: Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
Study: NCT03011008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Receive insulin following clinician's instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Receive insulin following clinician's instruction.
Study: NCT00764699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF (Increlex)
Description: rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
Study: NCT05296226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry needling and ischemic compression
Description: dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry needling and ischemic compression
Description: dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
Study: NCT01572597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10RAC+acetylcystein
Description: 10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10RAC+metronidazole
Description: 10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
Study: NCT04006041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Description: Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
Study: NCT01090479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine cloth
Description: The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
Study: NCT00469573

Intervention type: DRUG
Group type: OTHER
Intervention: 1. Optive
Description: Optive 15ml- (in the eye) Instill one drop twice daily in each eye
Study: NCT02107417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active TENS
Description: Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo TENS
Description: who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
Study: NCT04404426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Administration of citrulline enterally for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (water) enterally for 7 days
Study: NCT00190437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic
Description: Amoxicillin-clavulanic
Study: NCT00672555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limberg-flap
Description: Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
Study: NCT01941511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
Study: NCT01991392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: For nasogastric decompression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No nasogastric tube
Description: For nasogastric decompression.
Study: NCT01019187

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary Studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary Studies
Study: NCT04393753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domatinostat in combination with avelumab
Description: domatinostat tablets and avelumab infusion
Study: NCT01493843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pictilisib
Description: Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pictilisib
Description: Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pictilisib
Description: Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
Study: NCT01019187

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fatigue Assessment and Management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep Disorder Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary Studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fatigue Assessment and Management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep disorder therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of Life assessment
Description: Ancillary Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fatigue assessment and management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of therapy and complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep disorder therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Quality of Life Assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary Studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fatifue assessment and management
Study: NCT00703456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: balance training three days per week for 4 weeks during single limb standing
Study: NCT03182374

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nSTRIDE APS
Description: Intra-articular injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Intra-articular injection
Study: NCT04218201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCP brief advice
Description: Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
Study: NCT01493843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
Study: NCT04218201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video doctor
Description: During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone health coaching
Description: All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Care Manager (NCM) intervention
Description: NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
Study: NCT01493843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
Study: NCT04487041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard dose influenza vaccination
Description: Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard dose influenza vaccination
Description: Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose influenza vaccination
Description: Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard dose influenza vaccination
Description: Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose influenza vaccination
Description: 4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose influenza vaccination
Description: 4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose influenza vaccination
Description: 4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose influenza vaccination
Description: 4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
Study: NCT02854072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
Study: NCT03628092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Fractional Ablative Laser
Description: Vaginal / vulval laser treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham Device
Study: NCT02182895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 2.5-5 mg daily
Study: NCT03938311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early rehabilitation
Description: The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early rehabilitation
Description: The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early rehabilitation
Description: The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed.
Study: NCT02492035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study: NCT03002441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Same-Day Dilapan-S
Description: Dilapan-S cervical dilators placed the same day as the D\&E procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overnight Dilapan-S
Description: Dilapan-S cervical dilators placed the day prior to D\&E procedure
Study: NCT04310540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET